trending Market Intelligence /marketintelligence/en/news-insights/trending/IqK5kYPqADt00Ro7359Z2g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Jenex to initiate test against Zika, West Nile viruses

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Jenex to initiate test against Zika, West Nile viruses

The Jenex Corp. plans to test TherOZap, its next-generation technology, against the Zika and West Nile viruses.

Jenex enlisted an independent lab and healthcare network to conduct the tests, which will determine whether the technology can be effective in deactivating the viruses. The company said it will provide an update on initial test results in the near future.

The U.S. FDA granted Jenex a class 2 medical device status for its platform technology, which is indicated for the relief of pain, itch and inflammation caused by insect stings and bites.